US Patent Issued to University of Pittsburgh-Of the Commonwealth System of Higher Education, National Research Council of Canada on Sept. 30 for "Engineered TGF-beta monomers and their use for inhibiting TGF-beta signaling" (Canadian, American Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,460, issued on Sept. 30, was assigned to University of Pittsburgh-Of the Commonwealth System of Higher Education (Pittsburgh) and National Research Council of Canada (Ottawa).

"Engineered TGF-beta monomers and their use for inhibiting TGF-beta signaling" was invented by Andrew Peterson Hinck (Pittsburgh) and Traian Sulea (Ottawa).

According to the abstract* released by the U.S. Patent & Trademark Office: "Recombinant transforming growth factor (TGF)-Beta monomers modified to inhibit dimerization and block TGF-Beta signaling are described. The recombinant TGF-Beta monomers lack the ability to bind and recruit TGF-Beta type I receptor (TBetaRI), but retain the capacity to bind the...